EGFR and lung cancer: To address the function of EGFR palmitoylation in lung cancer, we used an autochthonous genetically engineered mouse model of lung adenocarcinoma driven by oncogenic KrasG12D; in this mouse model, the progression to adenocarcinoma is accelerated by deletion of the tumour suppressor p53 [40,41].